Editas Medicine (EDIT) PT Lowered to $60 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts EDIT Hot Sheet
Price: $2.40 -3.61%
Rating Summary:
13 Buy, 12 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
13 Buy, 12 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Raymond James analyst Steven Seedhouse lowered the price target on Editas Medicine (NASDAQ: EDIT) to $60.00 (from $65.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Indusind Bank Ltd (IIB:IN) PT Lowered to INR875 at Axis Capital Limited
- Coforge Ltd (COFORGE:IN) PT Raised to INR2,550 at Nuvama
- Piper Sandler Upgrades TriCo Bancshares (TCBK) to Overweight
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
